Red Violet
RDVT
57 hedge funds and large institutions have $128M invested in Red Violet in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 27 increasing their positions, 17 reducing their positions, and 5 closing their positions.
59% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 17
0% more funds holding
Funds holding: 57 → 57 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
7.02% less ownership
Funds ownership: 60.78% → 53.76% (-7%)
11% less capital invested
Capital invested by funds: $143M → $128M (-$15.5M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $100K
Top Buyers
| 1 |
TI
Trigran Investments
Northbrook,
Illinois
|
+$9.38M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.04M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$1.64M |
| 4 |
BlackRock
New York
|
+$1.56M |
| 5 |
Goldman Sachs
New York
|
+$680K |
Top Sellers
RDVT Hedge Fund Activity: Q3 2022 in Review
57 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Red Violet (RDVT) for Q3 2022, worth a combined $128M — down 11% from $143M a quarter earlier.
Fund positioning in RDVT was balanced in Q3 2022: 5 funds opened new positions, 5 closed out, 27 added to existing stakes and 17 trimmed.
The largest buyer was Trigran Investments, adding an estimated $9.38M. The largest seller was Ophir Asset Management, cutting an estimated $21.3M.
- 57 institutional investors held Red Violet (RDVT) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $128M of Red Violet stock for Q3 2022, down 11% quarter-over-quarter.
- 5 funds opened new Red Violet positions in Q3 2022 and 5 closed out, a net change of 0 holders.
- The largest Red Violet buyer in Q3 2022 was Trigran Investments, an estimated $9.38M added.
- The largest Red Violet seller in Q3 2022 was Ophir Asset Management, an estimated $21.3M sold.
Based on aggregated 13F filings for Q3 2022.